2024 saw growth recovery for almost all top biopharma companies
Eli Lilly experienced the highest revenue growth of 32% to $45bn, followed by Novo Nordisk with 25.5% growth to $42.1bn.
Global Healthcare and Pharma Market Outlook
Obesity and T2D drugs drive Novo Nordisk and Eli Lilly Q2 2023 growth
Risk sharing agreements soar as market access risk increases
Inflationary storm clouds will continue to buffet global pharma industry in 2023
Inflation, drug pricing and reimbursement constraints will challenge pharma sector
The top ten pharma companies best positioned to weather future industry disruption
BioMarin’s Voxzogo obtains Japan’s MHLW approval for achondroplasia
Longevity technology and its future
